Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
Sreeram V RamagopalanRiccardo PisoniAleksandr A ZeninLokendra Singh RathoreJoshua RayCormac SammonPublished in: Journal of comparative effectiveness research (2020)
Aim: To investigate the comparative effectiveness of trastuzumab emtansine (T-DM1) in a real-world population of HER2+ metastatic breast cancer (mBC) patients. Materials & methods: The Flatiron Health database was used to identify a cohort of HER2+ mBC patients who received first-line trastuzumab treatment and T-DM1 or lapatinib plus chemotherapy as second-line treatment. Overall survival was compared between the two groups. Results: A total of 278 patients with HER2+ mBC received second-line T-DM1 and 34 lapatinib plus chemotherapy. Overall survival was longer in patients treated with T-DM1 than those treated with lapatinib plus chemotherapy (adjusted hazard ratio: 0.56; 95% CI: 0.38-0.85). Conclusion: Real-world data supports the effectiveness of T-DM1 in the second-line treatment of HER2+ mBC patients.
Keyphrases
- metastatic breast cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- positive breast cancer
- public health
- randomized controlled trial
- healthcare
- peritoneal dialysis
- systematic review
- prognostic factors
- squamous cell carcinoma
- radiation therapy
- glycemic control
- type diabetes
- mental health
- patient reported outcomes
- adipose tissue
- machine learning
- rectal cancer
- artificial intelligence
- data analysis
- insulin resistance
- adverse drug